| 张 颐,于爱军,袁 航,等.上皮性卵巢癌复发风险评估方法学中国专家共识（2025年版）[J].肿瘤学杂志,2026,32(1):2-12. |
| 上皮性卵巢癌复发风险评估方法学中国专家共识（2025年版） |
| Chinese Expert Consensus on Risk Assessment Methodology for Epithelial Ovarian Cancer （Version 2025） |
| 投稿时间：2025-06-03 |
| DOI：10.11735/j.issn.1671-170X.2026.01.B002 |
|
 |
| 中文关键词: 卵巢肿瘤 复发 风险评估 专家共识 |
| 英文关键词:ovarian neoplasms recurrence risk assessment expert consensus |
| 基金项目:辽宁省重点研发项目（2024JH2/102500019）；辽宁省“兴辽英才计划”项目（XLYC2412037）；2022年沈阳市科技计划（22-321-33-08）；沈阳市科技局2023年助力中国医科大学高质量发展专项（23-506-3-01-10） |
|
| 摘要点击次数: 0 |
| 全文下载次数: 1 |
| 中文摘要: |
| 摘 要：卵巢癌是女性生殖系统常见恶性肿瘤之一，大多数上皮性卵巢癌患者对化疗敏感，经标准一线方案治疗后可达到完全或部分缓解。尽管已联合采用手术、化疗及基于生物标志物的维持治疗方案，绝大多数上皮性卵巢癌患者仍会出现疾病的复发。复发性卵巢癌患者即便接受进一步的规范化治疗，后线治疗的耐药率仍逐渐增高，给临床治疗带来极大挑战。因此，准确识别和预判高复发风险人群，对改善卵巢癌患者预后具有积极意义。本共识基于文献证据，制定卵巢癌复发风险评估的方法学依据，供临床借鉴参考。 |
| 英文摘要: |
| Abstract： Ovarian cancer is one of the most common malignancies of the female reproductive system. Although most patients with epithelial ovarian cancer (EOC) are sensitive to chemotherapy and achieve complete or partial remission after standard first-line treatment， the vast majority will experience disease recurrence despite combined modalities including surgery， chemotherapy， and biomarker-based maintenance therapy. Furthermore， even with further standardized treatment for recurrent disease， resistance to subsequent chemotherapy lines gradually increases， posing significant challenges for clinical management. Therefore， accurately identifying and predicting patients at high risk of recurrence is crucial for improving the prognosis of ovarian cancer patients. Based on current literature evidence， this consensus establishes a methodological framework for assessing the risk of ovarian cancer recurrence， intended for clinical reference. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |